Jeffrey Smith Email & Phone Number

Carlsbad, California, United States

We collaborate with advocacy organizations to advance shared priorities and improve the lives of people living with challenging illnesses.

We help clients make meaningful and sustainable connections and collaborations with advocacy communities in order to advance shared priorities and improve the lives of people living with serious illnesses.

I work with an outstanding team at Wave Life Sciences to develop and implement our vision for engaging and supporting the patient advocacy community. At Wave we're committed to delivering transformational therapies to people with serious, genetically-defined illnesses.

Worked every single day to make a difference in the lives of people living with multiple sclerosis (MS) and to make a substantial impact at Biogen.- As the Global and US Patient Advocacy Lead for MS, I spearheaded the development and execution of strategic patient advocacy plans intended to elevate the standard of care in MS and to build and foster substantive, collaborative relationships.- Served as the primary point-of-contact and internal champion for 9 high-priority MS patient advocacy organizations in the US advocacy community, in support of $9 billion (B) MS franchise at Biogen.- Collaborated with advocacy community on important initiatives to advance health policy priorities, educate and empower people living with MS, facilitate access to appropriate care, ensure awareness of clinical research efforts, and provide Biogen representation and perspective on key community activities.- Developed, coordinated and facilitated strategic advocacy engagement activities including an Advocacy Leadership Summit, a blinded Advocacy Perception Tracker survey, and leadership exchange meetings to identify and advance shared priorities and develop sustainable, mutually-beneficial partnerships.- Incorporated patient perspective into Biogen through the development of regular impact reports, participation in internal leadership meetings, and facilitation of employee-engagement events, such as lunch-and-learns, which collectively engaged well over 500 employees.- Promoted a consistent leadership presence in the MS community by facilitating participation in 4 high-priority community events, resulting in engagement with over 10,000 community members and supporters.

I helped to establish the US Medical Innovation and External Partnerships group in order to better meet the needs of patient advocacy organizations and other key external stakeholders. Partnered with key stakeholders such as healthcare providers, payers, and patient advocacy organizations to transform the delivery of care and improve outcomes for people living with MS, hemophilia, and other serious conditions. Worked to identify challenges and implement solutions - such as research and educational initiatives - to make a substantial long-term impact on the lives of patients.

- Developed and executed strategic and tactical commercialization plans for ALPROLIX in hemophilia B, contributing to launch surpassing analysts’ expectations by 50% six months post-launch. - Engaged and educated hemophilia HCPs, patients and the advocacy community to build trust, cultivate relationships, and establish Biogen as a leader in meeting the needs of the community.

- Developed and executed global and local commercial strategies for multiple internal drug development programs with over $3B combined annual revenue potential across hematology, immunology, and neurology. - Developed new therapeutic focus in immunology by leading a cross-functional team including commercial, medical, research, and clinical operations in analyzing and evaluating 24 disease areas for potential investment opportunities (led a similar initiative in hematology). - Directed primary market research initiatives engaging physicians, patients, and payers in global markets to inform development and execution of brand strategy for multiple therapeutic candidates. - Led commercial evaluation and forecast modeling for multiple business development and new venture opportunities, including one potentially $6+B acquisition candidate.

Mba, Strategy And Business Analysis; Health Sector Management

M.S., Biochemistry

B.S., Biochemistry

Education record